Aptiv (NYSE:APTV – Get Free Report) and Aspire Biopharma (NASDAQ:ASBP – Get Free Report) are both consumer discretionary companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, institutional ownership, earnings and risk.
Analyst Ratings
This is a summary of current recommendations for Aptiv and Aspire Biopharma, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aptiv | 2 | 4 | 18 | 1 | 2.72 |
| Aspire Biopharma | 1 | 0 | 0 | 0 | 1.00 |
Aptiv presently has a consensus target price of $74.80, suggesting a potential upside of 65.70%. Given Aptiv’s stronger consensus rating and higher possible upside, analysts plainly believe Aptiv is more favorable than Aspire Biopharma.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Aptiv | 1.17% | 17.10% | 7.03% |
| Aspire Biopharma | -11,362.21% | N/A | -177.59% |
Insider & Institutional Ownership
94.2% of Aptiv shares are owned by institutional investors. Comparatively, 19.2% of Aspire Biopharma shares are owned by institutional investors. 0.1% of Aptiv shares are owned by company insiders. Comparatively, 5.8% of Aspire Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Aptiv and Aspire Biopharma”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aptiv | $20.40 billion | 0.46 | $165.00 million | $1.06 | 42.58 |
| Aspire Biopharma | $10,000.00 | 1,166.20 | -$24.48 million | ($69.62) | -0.12 |
Aptiv has higher revenue and earnings than Aspire Biopharma. Aspire Biopharma is trading at a lower price-to-earnings ratio than Aptiv, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Aptiv has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500. Comparatively, Aspire Biopharma has a beta of 0.17, suggesting that its stock price is 83% less volatile than the S&P 500.
Summary
Aptiv beats Aspire Biopharma on 13 of the 15 factors compared between the two stocks.
About Aptiv
Aptiv PLC engages in design, manufacture, and sale of vehicle components in North America, Europe, Middle East, Africa, the Asia Pacific, South America, and internationally. The company provides electrical, electronic, and safety technology solutions to the automotive and commercial vehicle markets. It operates through two segments, Signal and Power Solutions, and Advanced Safety and User Experience. The Signal and Power Solutions segment designs, manufactures, and assembles vehicle’s electrical architecture, including engineered component products, connectors, wiring assemblies and harnesses, cable management products, electrical centers, and hybrid high voltage and safety distribution systems. Its Advanced Safety and User Experience segment provides critical technologies and services for vehicle safety, security, comfort, and convenience, such as sensing and perception systems, electronic control units, multi-domain controllers, vehicle connectivity systems, application software, autonomous driving technologies, and end-to-end DevOps tools. The company was formerly known as Delphi Automotive PLC and changed its name to Aptiv PLC in December 2017. Aptiv PLC was incorporated in 2011 and is based in Dublin, Ireland.
About Aspire Biopharma
Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.
Receive News & Ratings for Aptiv Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptiv and related companies with MarketBeat.com's FREE daily email newsletter.
